Overview
Public BiotechLSD
Formerly Cybin Inc., rebranded to Helus Pharma in January 2026. Developing CYB003 (deuterated psilocybin) for major depressive disorder in Phase 3 trials, and CYB004 for generalized anxiety disorder.
Visit WebsiteToronto, Canada
$300M
Market Cap
2019
Founded
70
Employees
0
Open Roles
Open Positions
No open positions at this time